Business Information
The group's principal activities are to research, develop, license, manufacture and market proprietary drug delivery systems and products. The drug delivery technology involves releasing a drug into the bloodstream or delivering it to a certain site in the body at predetermined rates or at predetermined times. The products include drugs, which provide therapeutic benefits for pain, angina, hypertension, allergy and infection. The trademarks of the group include albulite cr, nifelite cr, diltilite CD, ketolite cr, verelite cr and glucolite cr.
|
|
Name |
Title
|
Email
|
| Bernard Berk | Chmn., CEO, Pres. | N/A | | Mark Gittelman | CFO, Sec., Treasurer | N/A | | Veerappan Subramanian | Dir., Chief Scientific Officer | N/A | | Chris Dick | Sr. VP - Business Development | N/A | | Barry Dash | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 551 | (6,884) | | 2005 | 301 | (5,907) | | 2004 | 258 | (6,514)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
